These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 37042320)

  • 1. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?
    Gawali P; Saraswat A; Bhide S; Gupta S; Patel K
    Nanomedicine (Lond); 2023 Jan; 18(2):169-190. PubMed ID: 37042320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
    Greish K
    J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms.
    Zi Y; Yang K; He J; Wu Z; Liu J; Zhang W
    Adv Drug Deliv Rev; 2022 Sep; 188():114449. PubMed ID: 35835353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
    Prabhakar U; Maeda H; Jain RK; Sevick-Muraca EM; Zamboni W; Farokhzad OC; Barry ST; Gabizon A; Grodzinski P; Blakey DC
    Cancer Res; 2013 Apr; 73(8):2412-7. PubMed ID: 23423979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.
    Kim J; Cho H; Lim DK; Joo MK; Kim K
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery.
    Dhaliwal A; Zheng G
    Theranostics; 2019; 9(26):8091-8108. PubMed ID: 31754383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Passive Targeting to Personalized Nanomedicine: Multidimensional Insights on Nanoparticles' Interaction with the Tumor Microenvironment.
    Sebak AA; El-Shenawy BM; El-Safy S; El-Shazly M
    Curr Pharm Biotechnol; 2021; 22(11):1444-1465. PubMed ID: 33308126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
    Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
    Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation.
    Ikeda-Imafuku M; Wang LL; Rodrigues D; Shaha S; Zhao Z; Mitragotri S
    J Control Release; 2022 May; 345():512-536. PubMed ID: 35337939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y; van der Meel R; Chen X; Lammers T
    Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor targeting via EPR: Strategies to enhance patient responses.
    Golombek SK; May JN; Theek B; Appold L; Drude N; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2018 May; 130():17-38. PubMed ID: 30009886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
    Greish K
    Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.
    Natfji AA; Ravishankar D; Osborn HMI; Greco F
    J Pharm Sci; 2017 Nov; 106(11):3179-3187. PubMed ID: 28669714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors.
    Islam R; Maeda H; Fang J
    Expert Opin Drug Deliv; 2022 Feb; 19(2):199-212. PubMed ID: 33430661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving nanotherapy delivery and action through image-guided systems pharmacology.
    Ng TSC; Garlin MA; Weissleder R; Miller MA
    Theranostics; 2020; 10(3):968-997. PubMed ID: 31938046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor microenvironment and nanotherapeutics: intruding the tumor fort.
    Ravi Kiran AVVV; Kusuma Kumari G; Krishnamurthy PT; Khaydarov RR
    Biomater Sci; 2021 Nov; 9(23):7667-7704. PubMed ID: 34673853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting endothelial permeability in the EPR effect.
    Lahooti B; Akwii RG; Zahra FT; Sajib MS; Lamprou M; Alobaida A; Lionakis MS; Mattheolabakis G; Mikelis CM
    J Control Release; 2023 Sep; 361():212-235. PubMed ID: 37517543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.